Literature DB >> 12083741

Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia.

Motohisa Suzuki1, Mayumi Suzuki, Yukika Kitamura, Saori Mori, Kazunori Sato, Sekiko Dohi, Takashi Sato, Akihiro Matsuura, Atsushi Hiraide.   

Abstract

In our previous study, beta-hydroxybutyrate (BHB) was found to prolong survival time and to inhibit cerebral edema by improving energy metabolism in the hypoxia, anoxia and global cerebral ischemia models. In this study, the cerebroprotective effect of BHB was examined in rats with permanent (p)-occlusion and transient (t)-occlusion of middle cerebral artery (MCA). BHB (30 mg x kg(-1) x h(-1) was continuously administered through the femoral vein. In rats with p-MCA occlusion, BHB significantly reduced infarct area at 24 h after the occlusion, but not at 72 h after the occlusion. In rats with 2-h t-MCA occlusion followed by 22-h reperfusion, BHB significantly reduced cerebral infarct area, edema formation, lipid peroxidation and neurological deficits. Moreover, in the t-MCA occlusion model, delayed administration of BHB started at 1 h after the initiation of the MCA occlusion also significantly reduced cerebral infarct area. Taking together the results obtained in our previous study into account, these results indicate that BHB decreased cerebral edema formation and infarct area by improving of the cerebral energy metabolism during ischemia and by inhibition of lipid peroxidation after reperfusion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12083741     DOI: 10.1254/jjp.89.36

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  49 in total

1.  D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition in vivo.

Authors:  Jana Mejía-Toiber; Teresa Montiel; Lourdes Massieu
Journal:  Neurochem Res       Date:  2006-11-18       Impact factor: 3.996

Review 2.  Potential for discovery of neuroprotective factors in serum and tissue from hibernating species.

Authors:  Austin P Ross; Kelly L Drew
Journal:  Mini Rev Med Chem       Date:  2006-08       Impact factor: 3.862

Review 3.  Neuroprotective and disease-modifying effects of the ketogenic diet.

Authors:  Maciej Gasior; Michael A Rogawski; Adam L Hartman
Journal:  Behav Pharmacol       Date:  2006-09       Impact factor: 2.293

Review 4.  Cerebral metabolic adaptation and ketone metabolism after brain injury.

Authors:  Mayumi L Prins
Journal:  J Cereb Blood Flow Metab       Date:  2007-08-08       Impact factor: 6.200

5.  Protection of hypoglycemia-induced neuronal death by β-hydroxybutyrate involves the preservation of energy levels and decreased production of reactive oxygen species.

Authors:  Alberto Julio-Amilpas; Teresa Montiel; Eva Soto-Tinoco; Cristian Gerónimo-Olvera; Lourdes Massieu
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-04       Impact factor: 6.200

6.  Decreased carbon shunting from glucose toward oxidative metabolism in diet-induced ketotic rat brain.

Authors:  Yifan Zhang; Shenghui Zhang; Isaac Marin-Valencia; Michelle A Puchowicz
Journal:  J Neurochem       Date:  2014-11-10       Impact factor: 5.372

Review 7.  Mitochondrial dysfunction induced by nuclear poly(ADP-ribose) polymerase-1: a treatable cause of cell death in stroke.

Authors:  Paul Baxter; Yanting Chen; Yun Xu; Raymond A Swanson
Journal:  Transl Stroke Res       Date:  2013-09-07       Impact factor: 6.829

8.  Shotgun proteomics analysis of hibernating arctic ground squirrels.

Authors:  Chunxuan Shao; Yuting Liu; Hongqiang Ruan; Ying Li; Haifang Wang; Franziska Kohl; Anna V Goropashnaya; Vadim B Fedorov; Rong Zeng; Brian M Barnes; Jun Yan
Journal:  Mol Cell Proteomics       Date:  2009-11-20       Impact factor: 5.911

9.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

Review 10.  Hypometabolism as a therapeutic target in Alzheimer's disease.

Authors:  Lauren C Costantini; Linda J Barr; Janet L Vogel; Samuel T Henderson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.